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Abstract
Background: The variability of NT-proBNP levels has been studied in heart failure, yet no data exist on these changes over
time in hypertensive patients. Furthermore, studies on the relationship between natriuretic peptides and inflammatory
status are limited.
Methodology/Principal Findings: 220 clinically and functionally asymptomatic stable patients (age 59613, 120 male) out of
252 patients with essential hypertension were followed up, and NT-proBNP was measured at baseline, 12 and 24 months.
No differences in NT-proBNP were found with respect to the basal stage in the hypertrophic group, but significant changes
were found in non-hypertrophic subjects. The reproducibility of NT-proBNP measurements was better in patients with
hypertrophy than in the non-hypertrophic group for the three intervals (stage I-basal; stage II-stage I; stage II-basal) with a
reference change value of 34%, 35% and 41%, respectively, in the hypertrophic group. A more elevated coefficient of
correlation was obtained in the hypertrophic group than in patients without hypertrophy: basal versus stage I (r=0.79,
p,0.0001 and r=0.59, p,0.0001) and stage I versus stage II (r=0.86, p,0.0001 and r=0.56, p,0.0001). Finally, levels of NT-
proBNP significantly correlated with sTNF-R1 (p,0.0001) and IL-6 (p,0.01) during follow-up. A multivariate linear regression
analysis showed that sTNF-R1 is an independent factor of NT-proBNP.
Conclusions/Significance: This work shows that there is good stability in NT-proBNP levels in a follow-up study of
asymptomatic patients with stable hypertension and left ventricular hypertrophy. As a consequence, assessment of NT-
proBNP concentrations may be a useful tool for monitoring the follow-up of hypertensive patients with hypertrophy.
Measured variations in peptide levels, exceeding 35% in a 12-month follow-up and 41% in a 24-month follow-up, may
indicate an increase in cardiovascular risk, and therefore implies adjustment in the medical treatment. In addition, this study
shows a link between neurohormonal and inflammatory activation in these patients.
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Introduction
Circulating levels of natriuretic peptides are elevated in states of
increased cardiac wall stress. B-type natriuretic peptide (BNP) and
amino-terminal propeptide of B-type natriuretic peptide (NT-
proBNP) concentrations are well established markers for the
diagnosis and prognosis of patients with heart failure [1–3].
Furthermore, the Task Force of the European Society of Car-
diology for the Diagnosis and Treatment of Chronic Heart Failure
recommends that a natriuretic peptide assay should be included in
the first step of the algorithm for the diagnosis of heart failure
together with electrocardiography and chest x ray findings, on the
basis of its strong negative predictive value.
Left ventricular hypertrophy (LVH) is the main mechanism of
compensation for hemodynamic overload in hypertension. It has
been shown that NT-proBNP serum levels are increased in
hypertensive patients with LVH [4]. This natriuretic peptide
predicts cardiovascular events and is considered a marker of
cardiovascular risk in the general population [5] and in patients
with hypertension [6]. Furthermore, in a recent study Paget et al.
show that this peptide is a powerful predictor of mortality in
hypertensive patients without heart failure [7]. Therefore, NT-
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used to monitor hypertensive patients.
Knowing the variations in NT-proBNP levels before the clinical
use of this peptide as a tool to monitor patients is crucial. However,
there is a limited number of studies addressing natriuretic peptide
variability, and these works have evaluated the biological variation
of BNP and NT-proBNP concentrations in both patients with
chronic heart failure and healthy people over a short (within a day,
week to week and month to month) and intermediate (1-
month, 2-month, and 3-month) interval of time [8–11].
Schou et al. and our group have shown in previous works the
variability of NT-proBNP levels in patients with stable heart
failure during a 24-month follow-up [12,13], yet to date, there are
no data on the changes in serum NT-proBNP levels over time in
asymptomatic stable patients with essential hypertension. This
would allow us to know the usefulness of this peptide in the clinical
arena.
Several lines of evidences support a role for TNF-alpha, its
soluble receptors and IL-6 as predictors of cardiovascular events
[14,15]..In addition, in a previous report, our group showed that
the profile of circulating cytokines was altered in patients with
essential hypertension [16]. However, studies on the relationship
between inflammatory markers and NT-proBNP are limited
[17,18]. In fact, to the best of our knowledge, cytokine levels
have never been correlated with NT-proBNP concentrations in
hypertensive patients.
We hypothesize that NT-proBNP levels may change over time
even in patients with clinically stable hypertension and this peptide
could be associated with inflammatory status. Therefore, the
purpose of this study was to analyze NT-proBNP variability during
a 24-month follow-up, and to evaluate the relationship between
NT-proBNP levels and circulating inflammatory markers (sTNF-
R1 and IL-6) in a cohort of stable asymptomatic hypertensive
patients.
Methods
Ethics statement
All patients gave written informed consent to participate in the
study. The project was approved by the local Ethics Committee
(Biomedical Investigation Ethics Committee of ‘‘La Fe’’ University
Hospital of Valencia, Spain) and conducted in accordance with
the guidelines of the Declaration of Helsinki.
Patients
The study was on 252 Caucasian asymptomatic hypertensive
consecutive out-patients (mean 6 SD age 60613 years, 136 male),
from 11 participating hospitals. All patients underwent a routine
physical examination, electrocardiogram, echo-Doppler study and
laboratory analyses. Physicians using a standardized protocol
measured systolic and diastolic blood pressure in the left arm of
seated subjects between 08:00 and 11:00 AM, following the
recommendations of The American Heart Association [19].
Patients were included in the study between August
2007 and October 2007. Of the 252 subjects, 220 asymptom-
atic (they did not refer any symptoms of cardiovascular origin,
specifically any symptoms of heart failure) and stable patients
(without cardiovascular events [6]) were included in the study (122
with LVH and 98 without LVH, mean 6 SD age 59613 years,
120 male). Thirty-two (13%) were excluded during follow-up (21
refused to continue, 9 could not be located, 1 patient had a stroke
and 1 patient had a myocardial infarction). We decided to analyze
separately patients with and without LVH, because of the
differences in cardiac structure and prognosis.
Patients analyzed in this study met this inclusion criteria: a
previous diagnosis of hypertension, as defined by the Seventh
Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure [19].
Furthermore, exclusion criteria were secondary HT, left ventric-
ular ejection fraction ,50, ischemic (medical history, echo-
Doppler, troponin T assay) or dilated cardiomyopathy, atrial
fibrillation, more than mild valvular disease, acute and chronic
liver or renal diseases, immunological diseases, HIV, alcoholism
and drug addiction and any other life-threatening disease.
At least 2 months before study enrollment all patients were on
stable medical therapy with angiotensin II receptor antagonist
50%, diuretics 45%, angiotensin-converting enzyme inhibitors
32%, b-blockers 21%, statins 26%, and calcium-channel blockers
19%. No statistically significant changes were observed in the
different drugs administered during follow-up. None of the 220
patients finally studied presented cardiovascular events (defined as
stroke, myocardial infarction or cardiovascular death) [6]. Body
mass index was calculated as the weight in kilograms divided by
height in meters squared, and obesity was defined as body mass
index .30 kg/m
2. Glomerular filtration rate was calculated using
the modified diet in renal disease equation [20]. All patients were
followed up until the end of the study at month 24, with a three-
stage sample collection: basal, 12 months (stage I) and 24 months
(stage II). All explorations were made in each stage.
The procedure was approved by the appropriate institutional
review boards or ethics review committees of each study center, and
the study was conducted in accordance with the guidelines of good
clinical practice and with ethical standards for human experimen-
tation established by the Declaration of Helsinki. Every patient
signed a written informed consent for their inclusion in the study.
NT-proBNP determination
Samples were collected under standardized conditions to minimize
sources of preanalytical variation. Venous blood was taken by ven-
ipuncture with the subjects in sitting position between 08:00 and 11:00
AM, centrifuged immediately, and frozen at 280uC. After thawing,
serum NT-proBNP levels were determined in a single laboratory using
the commercially available Elecsys proBNP sandwich, electrochemi-
luminescence immunoassay on an Elecsys 2010 Analyzer (Roche
Diagnostics, Mannheim, Germany). The results are expressed as pg/
ml (equivalent to ng/l, SI units). The lower detection limit was 5 pg/
ml, and intra-assay variation was 2.6%.
Cytokine and cytokine receptor determination
Venus blood was taken by venipuncture into pyrogen-free
vacuum tubes containing EDTA, as anticoagulant, with the
subjects in sitting position between 8:00 and 11:00 AM, cen-
trifuged immediately, frozen at 280uC and only thawed once.
Plasma concentrations of sTNF-R1 and IL-6 were determined at a
central laboratory by specific commercial sandwich enzyme-linked
immunosorbent assays (Hbt human sTNF-R1 ELISA test kit;
Hycult Biotechnology, The Netherlands; Strakine human IL-6
ELISA; Strathmann Biotec, Germany). The tests were quantified
at 450 nm in a dual-wavelength microplate reader (Sunrise;
TECAN, Austria) using Magellan software (version 2.5; TECAN,
Austria). The sTNF-R1 and IL-6 tests have limits of detection of
25 and 0.3 pg/ml, respectively. Our intra-assay and inter-assay
coefficients of variation were 6.5 and 9.1% for sTNF-R1 and 6.1
and 8.3% for IL-6, respectively.
Echo-Doppler study
The study was performed using standard hospital echocardio-
graphic systems equipped with 2.5–4 MHz transducers. The
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standard apical and parasternal long axis views. Doppler
echocardiogram images were stored on videotape and analyses
of recordings were performed in a central laboratory. M-Mode
and two-dimensional images, Doppler spectrum and color
Doppler were analyzed off-line. For each patient, four consecutive
beats were measured and averaged for each Doppler variable.
To obtain left ventricular ejection fraction, the area-length
method was used [21]. Left ventricular mass was measured
following the Devereux method [22] and in our study LVH was
defined as .46.7 g/m
2.7 in women and .49.2 g/m
2.7 in men
[23]. The following measurements were used for assess-
ment of LV diastolic dysfunction: 1) mitral flow
propagation velocity (Vp) was determined using the
previously described method [24]; 2) peak flow velocity
in early diastole (E-wave) and during atrial contraction
(A) was measured by pulsed Doppler at valve level,
calculating the E/A ratio; 3) early LV filling deceleration
time (DT) was measured as the distance (time) between
the projection of the peak velocity on the baseline and
the point where EF slope encounters the baseline; 4) the
inclination of the straight line of the ascending mitral
ring in M-mode recording shows maximum ascending
velocity (mm/s) of the mitral annulus during early
diastole. The maximum relaxation velocity (RVm) was
calculated as mean value of the maximal velocities in the
septal, lateral, posterior, and anterior portion of the
annulus [25]. Intra-observer variability was consecutively
evaluated in series of 40 patients. Variability was expressed as
the absolute difference divided by the mean value of echocardio-
graphic measurements, left ventricular mass variability being
8.466%.
Statistical analyses
Continuous variables are presented as mean 6 standard
deviation and categorical variables as a number of patients or
percentage. Results for each variable were tested for normality
using the Kolmogorov Smirnov method. NT-proBNP concentra-
tions exhibited a non-normal distribution and were presented as
the median and interquartile range and log transformed (and
proved to be normalized) before parametric correlation analysis.
Temporal changes in peptide levels and clinical characteristics
were analyzed using the paired Student’s t test, and categorical
variable changes were compared using the McNemar test.
Correlation between NT-proBNP at baseline, stage I, and stage
II was also determined using Pearson’s coefficient. Cytokine
concentrations exhibited a non-normal distribution and were log
transformed (and proved to be normalized) before parametric
correlation analysis. Furthermore, multivariate linear regression
analysis was performed using log-transformed NT-proBNP as
dependent variable and included age, gender, treatment, systolic
and diastolic blood pressure, total cholesterol, log-
transformed sTNF-R1 and log-transformed IL-6 as independent
variables. The discrimination of the best model was based on the
principle of least mean square and higher R-square.
To compare NT-proBNP levels in both the LVH and non-LVH
groups over two different time intervals (stage I - basal; stage II –
basal; stage II – stage I), we used the statistical method of Bland
Altman [26,27]. In this graphical method the percentage of
change in the averages ((NT-proBNP stage I – NT-proBNP
basal)/(average stage I + basal)) is plotted against the average of
the two NT-proBNP measurements. This expression is useful to
normalize and compare the data without taking into account the
magnitude of the NT-proBNP measurement. Based on this
approach, the limits of agreement were determined by the mean
difference plus or minus the coefficient of reproducibility (CR),
where CR was calculated as 1.966 SD of the percentage of
changes. In this case, a high CR indicates poor reproducibility.
The coefficient of variation (CV) is calculated following
CV=100 (standard deviation/mean). The total CV (CVt)
and the analytical CV (CVa) provided the basis for the
individual biological CV (CVi) following CVi=(CVt
2 –
CVa
2)
1/2. Reference change values (RCVs) were calcu-
lated from median CVt values, according to the formula
RCV=Z62
1/2 (CVa
2/na+CVi
2/ns)
1/2, where Z=1.96; na
is the number of replicate assays; and ns is the number
of patient samples to estimate each of the two home-
aostatic set points. A p value,0.05 was considered significant
for all measures. All statistical analyses were performed using the
SPSS statistical software package (SPSS Inc., Chicago, IL).
Results
The baseline characteristics and natriuretic peptide serum levels
of the hypertensive patients in the three stages according to
hypertrophy are shown in Tables 1 (LVH group, n=122) and 2
(non-LVH group, n=98). Significant differences in blood pressure
and total cholesterol levels were observed with respect to the basal
stage in both groups. Body mass index, heart rate, biochemical
values, left ventricular mass index and diastolic function variables
did not show any statistical changes. In addition, significant
differences were found in ejection fraction and NT-proBNP
concentration in the non-LVH group. Figure 1 shows the mean of
NT-proBNP serum levels over the entire study according to left
ventricular hypertrophy. No differences were found with respect to
the basal stage in the LVH group, but significant changes were
observed in non-LVH subjects. NT-proBNP levels were increased
in LVH hypertensive patients compared to patients without
hypertrophy (p,0.0001).
The reproducibility of NT-proBNP measurements was better in
patients with LVH than in those without LVH. Figure 2 shows the
Bland-Altman plots for changes in NT-proBNP serum levels in
patients with LVH over each of the intervals studied (A: stage I –
basal; B: stage II – stage I; C: stage II – basal). In the A interval,
93.4% of patients fell within 1.96 SD of the mean. The mean 6
SD percentage of change of peptide levels agreement was
2.9617.0, with a CR of 33%, and the mean ± SD absolute
change was 106±107 pg/ml. In the B interval, 96.7% of
patients fell within the range of 1.96 SD, with a mean percentage
of change of -1614.3, CR of 28%, and the mean value of
absolute change was 87±88 pg/ml. Finally, in the C
interval, 95.1% of patients fell within 1.96 SD of the mean, with
a mean change of 2.6618.4, CR of 36% and the mean value of
absolute change was 110±111 pg/ml. Figure 3 shows the
changes in NT-proBNP serum levels in patients without LVH in
the A, B and C intervals. The percentages of patients within 1.96
SD of the mean were 92.9%, 90.1% and 94.9%, respectively. The
values of the mean 6 SD percentage change and CR were
7.3624.2 with a CR of 47%; 29.4628.5 with a CR of 56%; and
21.7629.0 with a CR of 57%, respectively. The mean value of
absolute change was 32±38 pg/ml, 29±43 pg/ml and
31±45 pg/ml, respectively. For the group of hyperten-
sive patients with hypertrophy, percentage CVt and CVi
in the A interval was 12.3% and 12.1%, in the B interval
12.5% and 12.3%, and in the C interval 14.7% and
14.5%, respectively; and the corresponding RCVs were
34%, 35% and 41%. For the group of hypertensive
patients without hypertrophy, percentage CVt and CVi
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28.5% and 28.4%, and in the C interval 29.1% and
28.9%, respectively; and the corresponding RCVs were
58%, 79% and 81%. In addition, when we analyzed the
correlation between the different NT-proBNP measurements, a
more elevated coefficient of correlation was obtained in the LVH
group than in patients without LVH: basal versus stage I (r=0.79,
p,0.0001 and r=0.59, p,0.0001) and stage I versus stage II
(r=0.86, p,0.0001 and r=0.56, p,0.0001).
Finally, when we calculated the correlation between NT-
proBNP levels and the concentrations of the inflammatory
markers analyzed, a good coefficient of correlation was obtained
in the group of hypertensive patients with LVH. Serum levels of
NT-proBNP significantly correlated with plasma concentrations
of sTNF-R1 (p,0.0001) and IL-6 (p,0.01) during follow-up.
However, in the group of hypertensive patients without LVH
this relationship was lower (Tabl e3 ) .I na d d i t i o n ,am u l t i v a r i a t e
linear regression analysis was used to test the independent
predictive power of these inflammatory mediators (adjusted for
age, gender, blood pressure, total cholesterol and
treatment) on log-transformed NT-proBNP in the hypertensive
patients with LVH. In each of the intervals studied the best
model included log transformed sTNF-R1 as independent factor
(Table 4).
Discussion
In a homogeneous and representative group of the hypertensive
population we found good stability of NT-proBNP levels in
patients with clinically and functionally stable hypertension and
LVH. This is the first study to monitor changes in serum NT-
proBNP concentration over time in asymptomatic clinically stable
patients with essential hypertension, and this would allow us to
know its usefulness in the clinical setting. In addition, we found a
significant relationship between this natriuretic peptide and the
inflammatory status, especially in the group of hypertensive
patients with LVH.
The presence of left ventricular hypertrophy adversely affects
the prognosis of patients with arterial hypertension. NT-proBNP
can predict outcome in patients with hypertension and LVH
without left ventricular dysfunction or renal disease, independently
of traditional cardiovascular risk factors including high blood
pressure, renal function and electrocardiographic indexes
[6]. The knowledge of variations in NT-proBNP levels is
necessary before this peptide can be used clinically as a
Table 1. Clinical characteristics of patients with essential
hypertension and left ventricular hypertrophy over the entire
study (n=122): basal, stage I=at 12 months, stage II=at 24
months.
Variable Basal Stage I Stage II
Age (years) 65613 66613 67612
SBP (mm Hg) 151623 149623 144623{
DBP (mm Hg) 86611 85612 82611{
PP (mm Hg) 65620 64620 62620{
Heart rate (bpm) 70613 70611 69612
BMI (kg/m
2)3 1 653 1 653 2 65
GFR (ml/min/1.73 m
2)9 1 622 89626 89628
Total cholesterol (mg/dl) 212636 204634* 200631{
Na (mEq/l) 140651 4 1 631 4 1 63
Hemoglobin (mg/dl) 14611 4 611 4 61
Diabetes mellitus (%) 18 21 22
EF (%) 58655 8 655 9 65
E/A 0.8460.25 0.8460.21 0.8260.19
Vp (cm/s) 44610 46612 46611
DT (ms) 209640 206638 207630
RVm 41694 2 610 4269
LVMI (g/m
2.7)6 3 615 64614 64615
Serum NT-proBNP (pg/ml) 102 (45–236) 92 (62–188) 114 (61–265)
Results are shown as mean (SD) or percentage of subjects. NT-proBNP levels are
presented as the median and interquartile range.
BMI, body mass index; DBP, diastolic blood pressure; DT, deceleration time; E/A,
flow velocity in early diastole and during atrial contraction ratio; EF, ejection
fraction; GFR, glomerular filtration rate; LVMI, left ventricular mass index; NT-
proBNP, N-terminal pro-brain natriuretic peptide levels; PP, pulse pressure;
RVm, maximum longitudinal relaxation velocity of left ventricle; SBP, systolic
blood pressure. Significant difference versus basal levels; Vp, mitral flow
propagation velocity:
*p,0.05;
{p,0.01;
{p,0.0001.
doi:10.1371/journal.pone.0031189.t001
Table 2. Clinical characteristics of patients with essential
hypertension without left ventricular hypertrophy over the
entire study (n=98): basal, stage I=at 12 months, stage II=at
24 months.
Variable Basal Stage I Stage II
Age (years) 53611 54610 55612
SBP (mm Hg) 146617 135616{ 136614{
DBP (mm Hg) 88611 83610{ 8369{
PP (mm Hg) 58614 52612{ 53612{
Heart rate (bpm) 70612 71611 70610
BMI (kg/m
2)2 8 632 8 632 8 63
GFR (ml/min/1.73 m
2)9 3 625 94621 93621
Total cholesterol (mg/dl) 214640 206633* 206633*
Na (mEq/l) 141621 4 0 651 3 9 67
Hemoglobin (mg/dl) 14611 5 611 5 61
Diabetes mellitus (%) 17 20 21
EF (%) 59655 9 656 1 65*
E/A 1.0260.22 1.0560.27 1.0160.26
Vp (cm/s) 56685 6 611 57612
DT (ms) 186628 183622 184622
RVm 50695 3 611 54612
LVMI (g/m
2.7)3 9 663 9 663 9 69
Serum NT-proBNP (pg/ml) 33 (16–54) 39 (27–60){ 37 (18–61)
Results are shown as mean 6 SD or percentage of subjects. NT-proBNP levels
are presented as the median and interquartile range.
BMI, body mass index; DBP, diastolic blood pressure; DT, deceleration time; E/A,
flow velocity in early diastole and during atrial contraction ratio; EF, ejection
fraction; GFR, glomerular filtration rate; LVMI, left ventricular mass index; NT-
proBNP, N-terminal pro-brain natriuretic peptide levels; PP, pulse pressure;
RVm, maximum longitudinal relaxation velocity of left ventricle; SBP, systolic
blood pressure. Significant difference versus basal levels; Vp, mitral flow
propagation velocity:
*p,0.05;
{p,0.01;
{p,0.0001.
doi:10.1371/journal.pone.0031189.t002
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the biological variation of BNP and NT-proBNP concen-
trations in both patients with chronic heart failure and
healthy people over a short (within a day, week to week
and month to month), intermediate (1-month, 2-month,
and 3-month), and long-term (year-to-year) interval of
time [8–13]. To date, there are no data on the changes in
serum NT-proBNP levels over time in patients with
essential hypertension. In this work, we evaluated the
biological variation of serum NT-proBNP levels in a 24-month
follow-up of clinically stable asymptomatic hypertensive patients.
In our 220 patients with clinically and functionally stable
hypertension there were neither cardiovascular events nor
differences in ventricular function, but ejection fraction showed
significant variation in stage II with respect to basal values in the
non-hypertrophic group (61% versus 59% mean) and we think
that this minimal change could be attributed to the methodology
used [28]. Moreover, we found significant differences for values of
blood pressure and total cholesterol in both groups, these variables
decreasing over time probably as a consequence of the treatment.
At first, we could think that these changes in blood pressure values
affect the natriuretic peptide concentrations during follow-up.
However, the results of the present study and previous works
have shown that blood pressure (systolic and diastolic) and total
cholesterol levels were not independent predictors of natriuretic
peptide levels in hypertensive patients [29,30]. In addition,
Frankenstein et al., showed that the individual biolog-
ical variability of NT-proBNP does not appear to be
influenced by known confounders, such as sex, age,
weight or waist circumference, ejection fraction, or
renal function [11].
When we compared the levels of NT-proBNP over time
according to LVH, we only found significant changes in stage II
with respect to basal values in the non-LVH group, but in LVH
patients NT-proBNP levels remained stable. Furthermore, good
correlation was obtained between NT-proBNP concentrations at
the three stages over the entire study, the correlation coefficients
being higher for the group of hypertensive patients with
hypertrophy. These findings also prove higher stability of NT-
proBNP levels in LVH patients with respect to non-LVH.
Another consideration of natriuretic peptide stability is that the
percentage change in our patients with LVH over the entire study
(24-month follow-up) presented an SD below 19%. In the non-
LVH group the SD was lower than 29%. In addition,
biological variability and the resulting RCVs were lower
in hypertrophic subjects. This difference between results may
occur because the peptide levels are closely regulated by specific
pathophysiological mechanisms, and although stretch of cardiac
myocytes is considered the main stimulus for NT-proBNP
secretion, certain physiology conditions can also stimulate peptide
release [31,32]. In other words, in patients presenting LVH there
is a predominant stimulus for the synthesis of NT-proBNP which is
cardiac wall stress [33], however, in patients without ventricular
hypertrophy the peptide concentrations found in the bloodstream
could be a consequence of diverse and variable physiological
conditions [34]. Furthermore, NT-proBNP immunoassay methods
had some variability and this may induce higher % variations in
patients showing lower peptide values.
One important clinical consequence of our study is the
establishment of an NT-proBNP percentage change, from which
we can monitor the progress of these patients. Thus, we suggest
that all NT-proBNP measured variations, with a coefficient of
reproducibility (.1.96 SD percentage change) above 33% in a 12-
month follow-up and 36% in a 24-month follow-up, could be
considered an increase in potential risk. In a previous study, our
group established a similar coefficient of reproducibility in patients
with heart failure (25%) in a 24-month follow-up [13]. Nowadays,
NT-proBNP usefulness to monitor heart failure patients is well
established [35]. In our group of hypertrophic patients
RCVs were 35% in a 12-month follow-up and 41% in a
24-month follow-up, meaning that concentrations had to
increase or decrease by these percentages to be assessed
as different from the previous measurement, with a 5%
error probability for falsely assessing a change as
Figure 1. Serum logarithm of NT-proBNP levels during a 24-month follow-up. Measurements represent the median value at basal (1), stage
I (2) and stage II (3). NT-proBNP, N-terminal pro-brain natriuretic peptide levels; stage I, 12-month follow-up; stage II, 24-month follow-up. **p,0.01
with respect to basal levels.
doi:10.1371/journal.pone.0031189.g001
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importance. These results are in concordance with an
analysis performed on stable heart failure patients [11].
In contrast, results of prior studies found RCVs around
100% [9,10]. The clinical relevance of these large RCVs
are controversial, but the key to understanding these
results is the definition of stability of heart failure and
also the estimation of CVs. We think there could be a clinical
shift in using natriuretic peptides to change management of those
with hypertension and LVH over time. The evidence has
clearly demonstrated that NT-proBNP is a powerful
predictor of mortality and cardiovascular risk in
hypertensive patients. This suggests the importance of
NT-proBNP in the assessment of these patients to
perform a more accurate risk evaluation and in the
future to possibly lead to an NT-proBNP guided therapy
able to get a more favorable clinical outcome.
Up-regulation and production of cytokines represent an intrinsic
or an innate stress response against myocardial injury and its
elevation predicts short- and long-term incidence of cardiovascular
adverse events [14,15]. In a previous report, our group showed
that the levels of different cytokines were increased in hypertensive
patients with LVH. Plasma cytokine levels, such as IL-6 and
sTNF-R1, were correlated with left ventricular mass index, but
when a logistic regression was performed to predict hypertrophy,
only sTNF-R1 was independent predictor [16]. Some authors
have shown that NT-proBNP serum levels are increased in
hypertensive patients with LVH [6,29]. In this sense, the results of
the present study are in concordance with these findings. We
found a good relationship between immune system activation and
natriuretic peptide levels in hypertensive patients with LVH,
specifically, a strong correlation between NT-proBNP and sTNF-
R1 concentrations. However, the molecular mechanisms by which
natriuretic peptides and inflammatory mediators are related are
uncertain. Ventricular wall stress is the principal factor stimulating
brain natriuretic peptide synthesis and release from cardiomyo-
cytes [36,37]. Furthermore, this stress also produces an increase in
cytokine levels, and the cytokines amplify the signal, because they
have a pleiotropic effect [38]. An interesting finding is that the
elevation in cytokine expression precedes the increase in
natriuretic peptides and collagen expression in a rodent model
of myocardial infarction [39]. These results could be translated to
other pathological conditions involving heart diseases. As inflam-
matory mediators are elevated in hypertensive patients with LVH,
this might explain in part the significant elevation of NT-proBNP
levels compared with patients without hypertrophy and therefore,
this also implies new therapeutic options to improve hypertension
treatment in the future. However, studies on the relationship
between inflammatory markers and natriuretic peptides are
limited. In fact, to the best of our knowledge, cytokine levels have
never been correlated with NT-proBNP concentrations in
hypertensive patients. Thus, more work is necessary to fully
understand the role of the cytokines studied in the activation of the
neurohormonal system.
One limitation of this study is that our patients were on
medication and it is known that NT-proBNP values could be
Figure 2. Bland-Altman plots for changes in NT-proBNP serum
levels in hypertensive patients with hypertrophy. Bland-Altman
plot showing agreement between the logarithm of NT-proBNP levels
percentage change against the average of the logarithm of NT-proBNP
levels in basal + stage I (A), stage I + stage II (B) and basal + stage II (C).
The solid line represents the mean of the percentage change. The
dashed lines define the limits of agreement (standard deviation of
percentage of change 61.96 SD). NT-proBNP, N-terminal pro-brain
natriuretic peptide levels; SD, standard deviation; stage I, 12-month
follow-up; stage II, 24-month follow-up.
doi:10.1371/journal.pone.0031189.g002
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enzyme inhibitors, angiotensin II receptor blockers, or beta-
blockers [40–42]. Nevertheless, this circumstance makes it easier
to extrapolate our data to the clinical practice. Moreover, we have
to admit that a larger group of patients would have provided
additional information. However, the strict inclusion-exclusion
criteria give our results greater value.
An important consideration is that we selected patients with
clinically stable hypertension without clinical or functional
changes, but we cannot rule out the possibility of subtle changes
in neurohormonal and immunology systems that might potentially
influence the variability of natriuretic peptide levels. However, we
think that because of this, our data are more useful for judging the
clinical variations in NT-proBNP levels, and they have evident
practical application.
Although we think that natriuretic peptides can be useful to
monitor hypertensive patients, this study has not been designed to
establish an optimal frequency of checking lab values. In addition,
it would be interesting from the clinical point of view to know
whether the variability in NT-proBNP levels is associated to events
occurring after the 2 years of the study in both the populations
studied (hypertensive patients with and without hypertrophy),
however, this study was designed and funded only for a 2-year
follow-up. Further studies would most definitely help clarify these
points.
Another potential limitation is that although echocardiography-
standardized techniques have been shown to be a more sensitive
tool for detecting LVH than electrocardiographic measurements
[43], the variability of this technique is higher than the variability
using magnetic resonance imaging. However, in this study a
specialized, blinded, single cardiologist performed the echocardio-
graphic analyses to measure the left ventricular mass to minimize
variability.
In conclusion, this work shows that there is good stability in NT-
proBNP levels in a 24-month follow-up study of asymptomatic
patients with clinically and functionally stable hypertension and
Table 3. Pearson’s coefficient (r) between log-transformed
serum NT-proBNP and inflammatory markers according to left
ventricular hypertrophy over the entire study: basal, stage
I=at 12 months, stage II=at 24 months.
With LVH (n=122) Without LVH (n=98)
log NT-proBNP (pg/ml) log NT-proBNP (pg/ml)
Basal Stage I Stage II Basal Stage I Stage II
log sTNF-R1 (pg/ml) 0.44{ 0.52{ 0.45{ 0.22* 0.24* 0.23*
log IL-6 (pg/ml) 0.29{ 0.31{ 0.28{ 0.11 0.18 0.14
log NT-proBNP, log-transformed N-terminal pro-brain natriuretic; LVH, left
ventricular hypertrophy; log IL-6, log-transformed interleukin-6; log sTNF-R1,
log-transformed soluble tumor necrosis factor receptor 1.
*p,0.05;
{p,0.01;
{p,0.0001.
doi:10.1371/journal.pone.0031189.t003
Figure 3. Bland-Altman plots for changes in NT-proBNP serum
levels in hypertensive patients without hypertrophy. Bland-
Altman plot showing agreement between the logarithm of NT-proBNP
levels percentage change against the average of the logarithm of NT-
proBNP levels in basal + stage I (A), stage I + stage II (B) and basal +
stage II (C). The solid line represents the mean of the percentage
change. The dashed lines define the limits of agreement (standard
deviation of percentage of change 61.96 SD). NT-proBNP, N-terminal
pro-brain natriuretic peptide levels; SD, standard deviation; stage I, 12-
month follow-up; stage II, 24-month follow-up.
doi:10.1371/journal.pone.0031189.g003
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predictive power of mortality and cardiovascular risk in
hypertension, assessment of NT-proBNP concentrations may be
a useful tool for monitoring the follow-up of hypertensive patients
with hypertrophy. Measured variations in peptide levels, exceed-
ing 35% in a 12-month follow-up and 41% in a 24-month follow-
up, may indicate an increase in cardiovascular risk, and therefore
implies adjustment in the medical treatment. In addition, this
study shows a link between neurohormonal and inflammatory
activation in these patients.
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